Author:
Curigliano Giuseppe,Spitaleri Gianluca,Fingert Howard J.,de Braud Filippo,Sessa Cristiana,Loh Elwyn,Cipolla Carlo,De Pas Tommaso,Goldhirsch Aron,Shah Rashmi
Reference28 articles.
1. Can pharmacogenetics help rescue drugs withdrawn from the market?;Shah;Pharmacogenomics,2006
2. Drug-induced prolongation of the QT interval;Roden;N Engl J Med,2004
3. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. [accessed 25.03.1997].
4. Food and Drug Administration. In: International conference on harmonisation; Guidance on E14 Clinical Evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed Regist 2005;70:61134–5.
5. MedWatch. Glaxo Wellcome voluntarily withdraws Raxar (grepafloxacin) [press release]. Rockville (MD): US Food and Drug Administration; October 1999. [accessed 22.10.2002].
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献